Moxifloxacina Anfarm (Moxifloxacin)

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in the respiratory, skin and abdominal systems.

• Community‑acquired pneumonia: achieves bacterial eradication and clinical recovery.
• Acute bacterial sinusitis: reduces sinus inflammation and clears infection.
• Acute bacterial exacerbation of chronic bronchitis: improves lung function and resolves bacterial load.
• Complicated skin and skin‑structure infections: eliminates pathogenic bacteria and promotes wound healing.
• Complicated intra‑abdominal infections: provides systemic antibacterial activity against mixed flora.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By binding to these enzymes, it prevents the unwinding of DNA, leading to halted bacterial cell division and ultimately bacterial cell death. This bactericidal action is effective against a wide range of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensation.
• Rash: mild skin erythema.
• Elevated liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or rupture, especially in the Achilles.
• QT interval prolongation: risk of cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis.
• Severe allergic reactions: anaphylaxis, angioedema.
• Hepatic failure: marked liver dysfunction.
• Seizures: rare neurologic events.

Before initiating therapy, clinicians should consider several safety measures.

• Assess renal function: adjust therapy if renal impairment is present.
• Monitor for tendon pain: discontinue if signs of tendonitis or rupture appear.
• Avoid concomitant QT‑prolonging drugs: reduce risk of arrhythmia.
• Use with caution in elderly patients: higher susceptibility to adverse events.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: increased risk of toxicity.
• Concurrent systemic corticosteroids: heightened tendon rupture risk.
• Combination with other QT‑prolonging agents: potential for serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish antibacterial activity.
• Antacids containing magnesium or aluminum: reduce oral absorption (relevant for oral forms).
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.